OmniAb (NASDAQ:OABI – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Friday, October 30th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $3.49 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:00 AM ET.
OmniAb (NASDAQ:OABI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.07. The company had revenue of $13.41 million for the quarter, compared to analysts’ expectations of $4.69 million. On average, analysts expect OmniAb to post ($0.35) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.
OmniAb Price Performance
Shares of OABI stock opened at $4.96 on Wednesday. The company’s fifty day simple moving average is $4.59 and its two-hundred day simple moving average is $2.66. OmniAb has a 1 year low of $1.30 and a 1 year high of $5.43.
Wall Street Analysts Forecast Growth
OABI has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Monday, August 17th. Leerink Partners upped their price objective on shares of OmniAb from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings raised shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.
Check Out Our Latest Stock Analysis on OABI
OmniAb Company Profile
OmniAb, Inc is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.
The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.
Featured Articles
- Five stocks we like better than OmniAb
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
